Exjade Clears European Commission 10 Months After FDA Approval
This article was originally published in The Pink Sheet Daily
Executive Summary
Novartis’ oral iron chelating agent was approved under priority review in the U.S. and carries a more specific indication in the EU.
You may also be interested in...
Novartis Exjade Clears FDA As First Oral Chelating Agent
Novartis receives broad indication for deferasirox for treatment of iron overload in patients over 2 years of age.
Novartis Institute For Tropical Diseases Could Have TB Drug In Clinic By Late 2007
Singapore-based institute is also looking at dengue fever and malaria, exec says in interview with “The Pink Sheet” DAILY.
Lilly To Settle Additional Zyprexa Liability Cases, Will Pay Up To $500 Million
Lilly will pay up to $500 million to settle the "vast majority" of claims alleging that the company failed to adequately warn patients of risks associated with the atypical antipsychotic Zyprexa (olanzapine), the firm announced Jan. 4